JO3479B1 - تركيبة دوائية مغلفة تحتوي على ريجورافنيب - Google Patents
تركيبة دوائية مغلفة تحتوي على ريجورافنيبInfo
- Publication number
- JO3479B1 JO3479B1 JOP/2013/0268A JOP20130268A JO3479B1 JO 3479 B1 JO3479 B1 JO 3479B1 JO P20130268 A JOP20130268 A JO P20130268A JO 3479 B1 JO3479 B1 JO 3479B1
- Authority
- JO
- Jordan
- Prior art keywords
- pharmaceutical composition
- composition containing
- coated pharmaceutical
- containing regorafenib
- regorafenib
- Prior art date
Links
- 239000002138 L01XE21 - Regorafenib Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004836 regorafenib Drugs 0.000 title abstract 2
- 239000002207 metabolite Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12183331 | 2012-09-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3479B1 true JO3479B1 (ar) | 2020-07-05 |
Family
ID=46963450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2013/0268A JO3479B1 (ar) | 2012-09-06 | 2013-09-04 | تركيبة دوائية مغلفة تحتوي على ريجورافنيب |
Country Status (43)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
| HUE035877T2 (en) * | 2013-09-13 | 2018-05-28 | Bayer Pharma AG | Pharmaceutical preparations containing Refametinib |
| CN104586808B (zh) * | 2014-12-27 | 2017-08-18 | 北京元延医药科技股份有限公司 | 抗肿瘤药物组合物 |
| CN105136956A (zh) * | 2015-09-11 | 2015-12-09 | 江苏嘉逸医药有限公司 | 一种快速测定瑞戈非尼含量的方法 |
| CN105267167A (zh) * | 2015-09-11 | 2016-01-27 | 江苏嘉逸医药有限公司 | 一种瑞戈非尼口服固体药物组合物的制备方法 |
| CN106880615A (zh) * | 2015-12-15 | 2017-06-23 | 北大方正集团有限公司 | 一种瑞戈非尼的口服固体制剂及其制备方法 |
| CN106880607A (zh) * | 2015-12-15 | 2017-06-23 | 北大方正集团有限公司 | 一种含有瑞戈非尼的口腔崩解片及其制备方法 |
| CN105496975B (zh) * | 2015-12-17 | 2019-01-04 | 河南润弘制药股份有限公司 | 一种瑞戈非尼片剂及其制备方法 |
| CN106913527A (zh) * | 2015-12-28 | 2017-07-04 | 江苏先声药业有限公司 | 一种瑞戈非尼速释微丸及其制备方法 |
| CN105879049B (zh) * | 2016-05-13 | 2019-03-26 | 浙江大学 | 一种瑞戈非尼与β-环糊精的包合物及其制备方法 |
| CN107661296A (zh) * | 2016-07-27 | 2018-02-06 | 江苏先声药业有限公司 | 一种瑞戈非尼固体分散体及其制备方法 |
| PE20200859A1 (es) * | 2017-06-02 | 2020-08-25 | Bayer Healthcare Llc | Combinacion farmaceutica que comprende regonafenib y nivolumab como anticancerigeno |
| EP3817744A4 (en) * | 2018-07-06 | 2022-07-13 | Agios Pharmaceuticals, Inc. | IVOSIDENIB FORMS AND PHARMACEUTICAL COMPOSITIONS |
| CN111053751A (zh) * | 2018-10-16 | 2020-04-24 | 正大天晴药业集团股份有限公司 | 瑞戈非尼的缓释片剂及其制备方法 |
| TWI799599B (zh) * | 2019-06-06 | 2023-04-21 | 華納國際生物科技股份有限公司 | 醫藥或保健品自乳化固體分散組成物 |
| EP3861989A1 (en) | 2020-02-07 | 2021-08-11 | Bayer Aktiengesellschaft | Pharmaceutical composition containing regorafenib and a stabilizing agent |
| CN112587485A (zh) * | 2021-01-08 | 2021-04-02 | 湖南南新制药股份有限公司 | 一种药物固体分散体及其制备方法 |
| CN113018274A (zh) * | 2021-03-10 | 2021-06-25 | 药源生物科技（启东）有限公司 | 一种含羟丙甲纤维素的药物组合物及其制备方法 |
| WO2024191389A1 (en) * | 2023-03-10 | 2024-09-19 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | A pharmaceutical composition of regorafenib |
| WO2025242583A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Novel formulation comprising elinzanetant in a solid dispersion |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4694841B2 (ja) * | 2002-09-20 | 2011-06-08 | アンドルックス ラボズ リミテッド ライアビリティ カンパニー | ビグアニドおよびチアゾリジンジオン誘導体を含有する多段階製剤 |
| CN1265793C (zh) * | 2002-11-18 | 2006-07-26 | 杭州容立医药科技有限公司 | 左西替利嗪伪麻黄碱复方口服制剂及制备方法 |
| EA010485B1 (ru) | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
| MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
| EP1962842A1 (en) * | 2005-12-15 | 2008-09-03 | Bayer HealthCare AG | Diaryl ureas for treating inflammatory skin, eye and/or ear diseases |
| AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| WO2008044111A1 (en) * | 2006-10-13 | 2008-04-17 | Pfizer Products Inc. | Pharmaceutical formulation tablet |
| WO2008073759A2 (en) * | 2006-12-07 | 2008-06-19 | Eli Lilly And Company | An article comprising prasugrel |
| WO2009054550A1 (en) * | 2007-10-25 | 2009-04-30 | Bayer Yakuhin, Ltd. | Nifedipine-containing press coated tablet and method of preparing the same |
| AR081060A1 (es) * | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
| KR20200003219A (ko) * | 2011-05-20 | 2020-01-08 | 아스트라제네카 유케이 리미티드 | 로수바스타틴 칼슘의 약학 조성물 |
-
2013
- 2013-09-04 UY UY0001035006A patent/UY35006A/es active IP Right Grant
- 2013-09-04 AR ARP130103145A patent/AR092439A1/es not_active Application Discontinuation
- 2013-09-04 JO JOP/2013/0268A patent/JO3479B1/ar active
- 2013-09-05 CN CN202010052300.XA patent/CN111249247A/zh active Pending
- 2013-09-05 CA CA2883767A patent/CA2883767C/en active Active
- 2013-09-05 PL PL13762967T patent/PL2892507T3/pl unknown
- 2013-09-05 EA EA201590520A patent/EA027685B1/ru not_active IP Right Cessation
- 2013-09-05 ES ES13762967.1T patent/ES2623205T3/es active Active
- 2013-09-05 EP EP13762967.1A patent/EP2892507B1/en active Active
- 2013-09-05 UA UAA201502818A patent/UA115994C2/uk unknown
- 2013-09-05 SI SI201330621T patent/SI2892507T1/sl unknown
- 2013-09-05 CU CUP2015000020A patent/CU24244B1/es unknown
- 2013-09-05 IN IN1673DEN2015 patent/IN2015DN01673A/en unknown
- 2013-09-05 MX MX2015002815A patent/MX359922B/es active IP Right Grant
- 2013-09-05 AU AU2013312531A patent/AU2013312531B2/en active Active
- 2013-09-05 PT PT137629671T patent/PT2892507T/pt unknown
- 2013-09-05 WO PCT/US2013/058257 patent/WO2014039677A1/en not_active Ceased
- 2013-09-05 EP EP17153541.2A patent/EP3243508A1/en not_active Withdrawn
- 2013-09-05 RS RS20170400A patent/RS56019B1/sr unknown
- 2013-09-05 MY MYPI2015700672A patent/MY176135A/en unknown
- 2013-09-05 HR HRP20170620TT patent/HRP20170620T1/hr unknown
- 2013-09-05 SG SG11201501683WA patent/SG11201501683WA/en unknown
- 2013-09-05 CN CN201380049461.1A patent/CN104902878A/zh active Pending
- 2013-09-05 DK DK13762967.1T patent/DK2892507T3/en active
- 2013-09-05 MA MA37888A patent/MA37888B1/fr unknown
- 2013-09-05 AP AP2015008292A patent/AP2015008292A0/xx unknown
- 2013-09-05 HK HK16102327.2A patent/HK1214170A1/zh unknown
- 2013-09-05 BR BR112015004936-2A patent/BR112015004936B1/pt active IP Right Grant
- 2013-09-05 HU HUE13762967A patent/HUE032758T2/en unknown
- 2013-09-05 CN CN202310406916.6A patent/CN116392598A/zh active Pending
- 2013-09-05 LT LTEP13762967.1T patent/LT2892507T/lt unknown
- 2013-09-05 CN CN202310410047.4A patent/CN116392485A/zh active Pending
- 2013-09-05 PE PE2015000289A patent/PE20151005A1/es active IP Right Grant
- 2013-09-05 TW TW102131928A patent/TWI640329B/zh active
- 2013-09-05 KR KR1020157008402A patent/KR102162036B1/ko active Active
- 2013-09-05 NZ NZ705578A patent/NZ705578A/en unknown
- 2013-09-05 US US14/018,516 patent/US20140065212A1/en not_active Abandoned
- 2013-09-05 CN CN202310409897.2A patent/CN116392484A/zh active Pending
- 2013-09-05 JP JP2015531194A patent/JP6445436B2/ja active Active
-
2015
- 2015-02-22 IL IL237350A patent/IL237350B/en active IP Right Grant
- 2015-03-02 ZA ZA2015/01394A patent/ZA201501394B/en unknown
- 2015-03-03 PH PH12015500460A patent/PH12015500460A1/en unknown
- 2015-03-04 SA SA515360113A patent/SA515360113B1/ar unknown
- 2015-03-05 CL CL2015000544A patent/CL2015000544A1/es unknown
- 2015-03-05 CR CR20150114A patent/CR20150114A/es unknown
- 2015-03-05 GT GT201500053A patent/GT201500053A/es unknown
- 2015-03-05 CO CO15050805A patent/CO7310528A2/es unknown
-
2017
- 2017-04-21 CY CY20171100450T patent/CY1118839T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500460A1 (en) | Coated pharmaceutical composition containing regorafenib | |
| WO2013188273A8 (en) | Topical ophthalmological pharmaceutical composition containing axitinib | |
| WO2013188268A8 (en) | Topical ophthalmological pharmaceutical composition containing pazopanib | |
| PH12015500587A1 (en) | Combination of regorafenib and acetylsalicylic acid for treating cancer | |
| MX2012012571A (es) | Dicarboxamidas de ciclopropilo y analogos que muestran actividades anti-cancerosas y anti-proliferativas. | |
| WO2013188283A8 (en) | Topical ophthalmological pharmaceutical composition containing sunitinib | |
| TN2013000533A1 (en) | Topical ophthalmological pharmaceutical composition containing regorafenib | |
| TN2015000280A1 (en) | Topical Ophthalmological Pharmaceutical Composition containing Regorafenib | |
| MX351180B (es) | Composicion farmaceutica que comprende derivados de piridona. | |
| WO2013188279A8 (en) | Topical ophthalmological pharmaceutical composition containing cediranib | |
| IN2014DN07897A (enExample) | ||
| WO2013114397A3 (en) | Pharmaceutically acceptable salt of brinzolamide and composition thereof | |
| DOP2015000049A (es) | Composición farmacéutica recubierta que contiene regorafenib | |
| PH12015501179A1 (en) | Fixed dose pharmaceutical composition comprising mometasone and azelastine | |
| IN2014DN10683A (enExample) | ||
| IN2013MU03838A (enExample) |